Quantcast
Last updated on April 17, 2014 at 16:26 EDT

Latest glioblastoma multiforme Stories

2013-12-09 10:00:24

PKM2 controls mitosis, saving cancer cells from death and promoting brain tumor growth Researchers have caught a protein they previously implicated in a variety of cancer-promoting roles performing a vital function in cell division, survival and development of brain tumors. In a paper published in Molecular Cell, Zhimin Lu, Ph.D., professor of Neuro-Oncology at The University of Texas MD Anderson Cancer Center and colleagues report how a tumor-specific protein flips a crucial switch in...

2013-12-09 08:28:49

Company invites individual and institutional investors to log-on to view presentation NEW YORK, Dec. 9, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that their December 5th RetailInvestorConferences.com presentation is now available for on-demand viewing. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat glioblastoma...

2013-12-06 11:13:12

Researchers describe a novel mechanism by which glioblastoma tumors resist targeted therapies A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma (GBM), the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in...

2013-12-06 11:11:38

Tumor cells temporarily lose mutation to evade drugs targeting mutation A team of scientists, led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine, has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped. The...

2013-12-05 23:31:06

RiboMed Biotechnologies, Inc. and NuvOx Pharma today jointly announced that they have entered into a collaborative agreement that will utilize RiboMed’s epigenetic biomarker test, GliomaSTRAT™, to characterize tumors from brain cancer patients and correlate response to NuvOx’s new drug, NVX-108 in the treatment of Glioblastoma multiforme (GBM). Carlsbad, CA and Tucson, AZ (PRWEB) December 05, 2013 RiboMed Biotechnologies, Inc. and NuvOx Pharma today jointly announced that they have...

2013-12-05 08:31:00

Data Published in Molecular Cancer Therapeutics Underlines Potential of Drug Candidate in Cancer Treatment HEIDELBERG, Germany, Dec. 5, 2013 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today that the data published in the December issue of Molecular Cancer Therapeutics demonstrate effective antitumor activity of the company's drug candidate APG350, an activator for TRAIL receptors. The publication shows that APG350's novel molecular structure...

2013-12-04 12:27:00

BUFFALO, N.Y., Dec. 4, 2013 /PRNewswire/ -- Kinex Pharmaceuticals announced today that they have received Orphan Drug designation for KX02 for the treatment of gliomas, which are the most common and aggressive form of brain cancer. Orphan drug status qualifies Kinex for seven years of exclusivity after formal marketing approval, as well as further development incentives. KX02, a dual src/pre-tubulin inhibitor, is a small molecule drug that has shown potent inhibitory activity...

2013-12-02 16:23:39

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK, Dec. 2, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that Jeffrey Bacha, B.Sc., MBA, president & CEO, will present at RetailInvestorConferences.com. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat...

2013-11-29 23:23:38

In response to an article published by U.S. News & World Report, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, discusses a new drug combination that could eradicate glioblastoma. Bohemia, NY (PRWEB) November 29, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to an article published by U.S. News & World Report on November 25, 2013 that discusses how a new drug cocktail may...

2013-11-27 23:04:25

Alliance for Cancer Gene Therapy (ACGT) – a Stamford, CT-based non-profit devoted exclusively to treating and eradicating cancer with cell and gene therapies – has provided a $500,000 grant to combat glioblastoma, one of the most difficult types of brain cancer to treat. Visit http://www.ACGTFoundation.org. United States and Canada (PRWEB) November 27, 2013 Alliance for Cancer Gene Therapy (ACGT) – a Stamford, CT-based non-profit devoted exclusively to treating and eradicating...